About the Council
The Healthcare Council works to highlight the potential of new biotechnology solutions, the pipeline of their applications and defines the implications these new tools will have on the European regulatory and legislative framework.
New advances in biological sciences combined with the acceleration of technological applications are transforming how healthcare is delivered to patients.
The Healthcare Council develops proposals in areas across the healthcare biotechnology landscape including: advanced therapy medicinal products (ATMPs), medicines for rare diseases and children (OMPs), regulatory efficiencies, market access and procurement.
The Council delivers the Patient BioForum as the platform of exchange of views between patient organisations and healthcare biotechnology members. The Council also delivers the Healthcare BioForum as a platform for exchange across the larger biotechnology and business ecosystem.
The Council meets three times per year to issue strategic advice and overall vision. It is supported by Working Groups across priority topics.
Healthcare Biotechnology in Action
The Healthcare Biotechnology Council has priorities selected by Members for shared work throughout the year, delivered through working groups and Council meetings.
Our priorities encompass the most pressing issues of our members within EU policy that concerns healthcare biotechnology.
Biopharmaceutical Strategy Group
The working group is tasked with advocacy delivery on behalf of the Healthcare Council on immediate legislative priorities to ensure the specific needs of healthcare biotechnology are duly considered by European policymakers.
Orphan Medicinal Products Group
The working group is tasked with developing policies and recommendations relevant to rare diseases to ensure Europe has the right environment to support investments into research & development for rare diseases and ensure patients have access to novel biotechnology treatments across the region.
Advanced Therapeutic Medicinal Products Group
The working group is tasked with developing policies and recommendations relevant to ATMPs, including raising awareness on the transformative impact of ATMPs for patients and society, and the necessity to adapt healthcare systems to ensure that patients across the EU can fully benefit from such therapeutics.
Regulatory Affairs Group
The working group is tasked with developing policies and recommendation to enable a progressive regulatory framework for efficient uptake of new healthcare biotechnologies in the EU. The group actively engages with European regulators, including the European Medicines Agency.
Market Access & Resilience Expert Group
The expert group is tasked with developing policies and recommendations relevant to market access and EU resilience, including on shortages, procurement, and supply-chains.
EuropaBio Webinar – How will the revision EU General Pharmaceutical Legislation impact Europe’s innovation ecosystem and biotechnology companies?7 March @ 1:00 pm - 2:30 pm CET
- 29 February @ 9:00 am - 1 March @ 5:00 pm CET